Onconova sinks as Baxter backs away from oral rigosertib
This article was originally published in Scrip
Executive Summary
Onconova Therapeutics sank 36.3% to close at $2.55 per share on 3 February after the company revealed deep in a disclosure of its Phase III plans for intravenous rigosertib in higher-risk myelodysplastic syndrome (MDS) that its partner Baxter Healthcare will not pursue further development of oral rigosertib in lower-risk MDS.
You may also be interested in...
Asia Deal Watch: China’s BravoVax, US-based GeoVax Team Up On Coronavirus Vaccine
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.